1. Home
  2. UAN vs URGN Comparison

UAN vs URGN Comparison

Compare UAN & URGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo CVR Partners LP

UAN

CVR Partners LP

HOLD

Current Price

$121.56

Market Cap

1.3B

Sector

Industrials

ML Signal

HOLD

Logo UroGen Pharma Ltd.

URGN

UroGen Pharma Ltd.

HOLD

Current Price

$29.37

Market Cap

1.4B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
UAN
URGN
Founded
2007
2004
Country
United States
United States
Employees
N/A
N/A
Industry
Agricultural Chemicals
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.3B
1.4B
IPO Year
2008
2016

Fundamental Metrics

Financial Performance
Metric
UAN
URGN
Price
$121.56
$29.37
Analyst Decision
Strong Buy
Analyst Count
0
7
Target Price
N/A
$29.29
AVG Volume (30 Days)
49.7K
814.8K
Earning Date
04-29-2026
05-06-2026
Dividend Yield
7.91%
N/A
EPS Growth
61.98
N/A
EPS
4.72
N/A
Revenue
$606,038,000.00
$1,128,000.00
Revenue This Year
N/A
$129.09
Revenue Next Year
N/A
$70.96
P/E Ratio
$26.32
N/A
Revenue Growth
15.36
N/A
52 Week Low
$81.18
$3.61
52 Week High
$139.50
$32.37

Technical Indicators

Market Signals
Indicator
UAN
URGN
Relative Strength Index (RSI) 42.25 60.89
Support Level $120.05 $17.96
Resistance Level $139.42 $30.00
Average True Range (ATR) 4.66 1.88
MACD -0.98 -0.17
Stochastic Oscillator 10.32 61.54

Price Performance

Historical Comparison
UAN
URGN

About UAN CVR Partners LP

CVR Partners LP is a manufacturer and supplier of nitrogen fertilizer products. Its principal products include Urea Ammonium Nitrate (UAN) and ammonia. The company market ammonia products to industrial and agricultural customers and UAN products to agricultural customers. The primary geographic markets for its fertilizer products are Kansas, Missouri, Nebraska, Iowa, Illinois, Colorado, and Texas. The company's product sales are heavily weighted toward UAN.

About URGN UroGen Pharma Ltd.

UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. The company's flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with Zusduri (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. The revenue source for the company comes from sales of the Company's approved products, Jelmyto and Zusduri, principally conducted in the United States.

Share on Social Networks: